doctype html
html(lang="en")
	head
		- var page = { home: "", rasStory: "", firstLine: "", thirdLine: "", administration: "", patientProfiles: "is-current", access: "", generic: "", paidHome: "" };
		include includes/_head.pug
		title Patient Profiles
	body
		form
			.pageWrap
				include includes/_notifyMain.pug
				include includes/_headerMain.pug
				main
					.hero.profiles(style="background-image:url(img/content-images/patient-hero.png)")
						.hero-inner
							.hero-copy
								span.hero-zone Patient Profiles
					section#roy.profile
						.profile-header.mb-md-0
							h2 First-line
						.profile-content
							.profile-content-left.roy
								.profile-content-container.upper(data-lg="img/content-images/roy-large.png", data-sm="img/content-images/roy.png")
									.overlay-content
										.patient-info
											.line
												span Patient
												span Roy*
											.line
												span Gender
												span Male
											.line
												span Age
												span 64
											.line
												span Occupation
												span Middle-school teacher
										.qualifier
											span *A hypothetical case study of a patient eligible for first-line mCRC therapy.
								.profile-content-container.roy.placeholder
								.profile-content-container.orange
									img(src="img/content-images/roy-scan.png")
									p.reference.colorWhite ALT = alanine aminotransferase; AST = aspartate aminotransferase; CBC = complete blood count; CT = computed tomography; ECOG PS = Eastern Cooperative Oncology Group Performance Status; Hb = hemoglobin; mCRC = metastatic colorectal cancer; R0 resection = complete resection; WT = wild type. 
							.profile-content-right.roy
								.content
									h3.mb-4 What clinical characteristics affect your first-line treatment decision?
									p.lead Medical history
									ul
										li Mild hyperlipidemia, controlled on statin therapy
									p.lead Presentation
									ul
										li 3-month history of worsening constipation, bloating, and blood in stool
										li Colonoscopy confirmed 4 cm, nonobstructing mass in the left colon
									p.lead Pathology report
									ul
										li Moderately differentiated adenocarcinoma
									p.lead Performance status
									ul
										li ECOG PS = 1
									p.lead Laboratory results
									ul
										li ALT: 70 U/L; AST: 180 U/L
										li CBC: Moderate anemia (Hb: 9.2 g/dL)
									p.lead Mutational status
									ul
										li WT 
											em RAS 
											| (wild type in both 
											em KRAS 
											|  and 
											em NRAS)
									p.lead Imaging results
									ul
										li CT scan indicated liver-limited metastases: 2 bilobar lesions (right: 3.5 cm; left: 6.5 cm)
									p.lead Surgery consult on metastatic disease
									ul
										li Potentially resectable metastases, but not upfront R0 resection
										li Surgeon feels metastatic disease is potentially #[span.nowrap resectable—treatment] goal is to downgrade the tumor
									a.btn.btn-secondary.mt-4(href="") See first-line data
					section.profile#brian.profile
						.profile-header.mb-md-0
							h2 First-line
						.profile-content
							.profile-content-left.brian
								.profile-content-container.upper(data-lg="img/content-images/brian-large.png", data-sm="img/content-images/brian.png")
									.overlay-content
										.patient-info
											.line
												span Patient
												span Brian*
											.line
												span Gender
												span Male
											.line
												span Age
												span 62
											.line
												span Occupation
												span Auto mechanic
										.qualifier
											span *A hypothetical case study of a patient eligible for first-line mCRC therapy.
								.profile-content-container.brian.placeholder
								.profile-content-container.orange
									div(style='margin-bottom: 35px;')
										img(src="img/content-images/brian-scan.png" style='margin-bottom:0')
										p.reference.colorWhite Images are shown for illustrative purposes only
									p.reference.colorWhite ALT = alanine aminotransferase; AST = aspartate aminotransferase; CBC = complete blood count; CT = computed tomography; ECOG PS = Eastern Cooperative Oncology Group Performance Status; GERD = gastroesophageal reflux disease; Hb = hemoglobin; mCRC = metastatic colorectal cancer; WT = wild type. 
							.profile-content-right.brian
								.content
									h3.mb-4 What clinical characteristics affect your first-line treatment decision?
									p.lead Medical history
									ul
										li Mild GERD
									p.lead Presentation
									ul
										li Sought medical treatment for frequent episodes of moderate/severe, right upper quadrant pain
										li Patient also complains of shortness of breath and pleuritic pain. Pain has noticeably worsened over the last month
										li Taking frequent pain medication
										li Colonoscopy indicated a 5 cm, nonobstructing mass in sigmoid colon
									p.lead Pathology report
									ul
										li Moderately differentiated adenocarcinoma
									p.lead Performance status
									ul
										li ECOG PS = 1
									p.lead Laboratory results
									ul
										li ALT: 100 U/L; AST: 210 U/L
										li CBC: Mild/moderate anemia (Hb: 9.8 g/dL)
										li Bilirubin: 1.8 mg/dL
									p.lead Mutational status
									ul
										li WT 
											em RAS 
											| (wild type in both 
											em KRAS 
											| and 
											em NRAS
											| )
									p.lead Imaging results
									ul
										li CT scan indicated diffuse, bulky metastatic involvement of lung and liver
									p.lead Surgery consult on metastatic disease
									ul
										li Unresectable due to number of metastatic sites
									a.btn.btn-secondary.mt-4(href="") See first-line data
					section#connie.profile
						.profile-header.mb-md-0
							h2 Third-line
						.profile-content.pb-0
							.profile-content-left.connie
								.profile-content-container.tall.upper(data-lg="img/content-images/connie-large.png", data-sm="img/content-images/connie.png")
									.overlay-content
										.patient-info
											.line
												span Patient
												span Connie*
											.line
												span Gender
												span Female
											.line
												span Age
												span 68
											.line
												span Occupation
												span Salesperson
										.qualifier
											span *A hypothetical case study of a patient eligible for third-line mCRC therapy.
									.health-data.connie
										p.reference.colorWhite ALT = alanine aminotransferase; AST = aspartate aminotransferase; CBC = complete blood count; CT = computed tomography; ECOG PS = Eastern Cooperative Oncology Group Performance Status; Hb = hemoglobin; mCRC = metastatic colorectal cancer; PLT = platelet; WBC = white blood cell count; WT = wild type. 
								.profile-content-container.connie.placeholder
							.profile-content-right.connie
								.content
									h3.mb-4 What clinical characteristics affect your third-line treatment decision?
									p.lead Medical history
									ul
										li Osteoarthritis
									p.lead Presentation
									ul
										li Initial presentation of mild abdominal discomfort and mild anemia
										li Colonoscopy revealed a nonobstructing mass in the left colon
										li CT scan revealed liver and lung metastases that were unresectable
									p.lead Prior therapy
									ul
										li
											| First-line treatment: FOLFOX + bevacizumab
											ul.list-unstyled
												li &ndash; Progressed on therapy after 9 months
										li
											| Second-line treatment: FOLFIRI + bevacizumab
											ul.list-unstyled
												li &ndash; Progressed on therapy after 7 months with liver and lung metastases
									p.lead Performance status
									ul
										li ECOG PS = 1
									p.lead Laboratory results
									ul
										li ALT: 135 U/L; AST: 250 U/L
										li
											| CBC
											ul.list-unstyled
												li &ndash; WBC: 4.0 x 10#[sup 3] mL/µL
												li &ndash; Neutrophil: 1.6 x 10#[sup 3] mL/µL
												li &ndash; Hb: 9.0 g/dL
												li &ndash; PLT: 125 x 10#[sup 3] mL/µL
										li Bilirubin: 1.8 mg/dL
									p.lead Mutational status
									ul
										li
											| WT 
											em RAS 
											| (wild type in both 
											em KRAS 
											| and 
											em NRAS
											| )
									p.lead Imaging results
									ul
										li CT scan indicated diffuse metastatic involvement of lung and liver
									p.lead Surgery consult on metastatic disease
									ul
										li Unresectable due to number of metastatic sites
									a.btn.btn-secondary.mt-4(href="") See third-line data
									.health-data-placeholder.connie
				include includes/_notifyTray.pug
				include includes/_footerMain.pug

